Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Oncology

Gainers Bright Green Corp. (NASDAQ: BGXX) jumped 90.5% to close at $48.08 on Wednesday. Bright Green Corporation, went public on the NASDAQ Tuesday, becoming the first U.S. plant-touching company to list on a major U.S. stock exchange.

Benzinga

Sorrento Starts Mid-Stage Study Of Abivertinib In Prostate Cancer

The FDA has signed off Sorrento Therapeutics Inc's (NASDAQ:SRNE) investigational new drug application (IND) for Abivertinib (Fujovee) for Phase 2 MAVERICK study in metastatic castrate-resistant prostate cancer (mCRPC). The MAVERICK study will be conducted in a partnership with the Prostate Cancer Clinical Trials Consortium and will enroll participants with both abiraterone-naïve and abiraterone-progressing…

Benzinga

Stocks That Hit 52-Week Lows On Monday

On Monday, 198 companies reached new 52-week lows.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

More than 6,500 runners help raise almost 210,000 to help children with cancer in UK's biggest charity fun run

Almost £210,000 was raised for Children’s Cancer North after the UK's biggest charity fun run was held on Sunday at Gosforth Park

Chronicle Live

New cancer consultant signs up with NHS Tayside

It is hoped the positive news will ease pressure on the health board’s under-fire oncology department.

Daily Record

Why Are Cullinan Oncology Shares Rising Today?

Taiho Pharmaceutical Co Ltd will co-develop and co-commercialize Cullinan Oncology Inc (NASDAQ: CGEM) lead program, CLN-081/TAS6417.

Benzinga

BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology

BridgeBio Pharma Inc (NASDAQ:BBIO) has announced an exclusive license with Bristol Myers Squibb Co (NYSE:BMY) to develop and commercialize BBP-398, a potentially best-in-class SHP2 inhibitor, in oncology. Under the agreement terms, BridgeBio will receive an upfront payment of $90 million, up to $815 million in development, regulatory and sales milestone payments, and tiered royalties in…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Cancer nurse gives best care she can after personal tragedy with the illness

Stephanie is motivated to give the best care she can to her patients after experiencing personal tragedy

Liverpool Echo

The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Hospital worker who stole £19k from 'much loved' porter's estate spared jail

Kate Connelly, who worked as a hospital clerical officer, was made executor of Ken Sutherland's will just two days before he died of cancer.

Daily Record

Dying porter wanted to leave his life savings to the hospital that cared for him - he was betrayed by a greedy colleague

Ken Sutherland wanted to leave everything to Stepping Hill Hospital - he made cleric Kate Connelly, 41, an executor of his will but she spent £19,000 on herself

Manchester Evening News

Stocks That Hit 52-Week Lows On Wednesday

On Wednesday, 807 companies reached new 52-week lows.

Benzinga

Takeda Pharma Clocks 1% Increase In FY21 Core Profit, Expects Growth Momentum In FY22

Takeda Pharmaceutical Company Limited (NYSE:TAK) reported a fiscal 2021 core net profit of ¥663.7 billion, an increase of 1.3% from the prior year. Core earnings per share reached ¥425, up 1.2%. FY21 net profit declined 38.8% to ¥230.1 billion. Fiscal 2021 core revenue was ¥3.42 trillion, an underlying increase of 7.4%. Gastroenterology…

Benzinga

Labor pledges $1m to support the Hunter's Kaden Centre

Funds for 'groundbreaking' exercise oncology clinic that supports people with cancer and chronic illness.

Newcastle Herald

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Surface Oncology: Q1 Earnings Insights

Surface Oncology (NASDAQ:SURF) reported its Q1 earnings results on Monday, May 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Surface Oncology reported an EPS of $0.13.

Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session

Daily Mirror

Nurse, 24, whose 'clumsiness' and short temper turned out to be brain tumour

Fern Cameron, 24, noticed her mood was changing and she was getting more short-tempered and easily wound up, she was referred for an MRI scan which revealed a brain tumour

Benzinga

Stocks That Hit 52-Week Lows On Friday

On Friday, 1043 companies hit new 52-week lows.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Recap: Sierra Oncology Q1 Earnings

Sierra Oncology (NASDAQ:SRRA) reported its Q1 earnings results on Friday, May 6, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga

Guardant Health Clocks 22% Jump In Q1 Revenues, Reiterates FY22 Guidance

Guardant Health Inc's (NASDAQ:GH) Q1 FY22 revenues rose 22% Y/Y to $96.1 million, beating the consensus of $95.70 million. Guardant's precision oncology testing revenues grew 32% to $84.1 million, driven by the increase in clinical and biopharma testing. Development services and other revenues rose 20% to $12.0 million from $14.9 million in…

Benzinga

Illumina Reports 41% Dip In Q1 Profits Despite 12% Jump in Sales, Reaffirms FY22 Guidance

Illumina Inc's (NASDAQ:ILMN) Q1 FY22 revenues rose 12% Y/Y to $1.22 billion, in line with estimates. Nearly all revenues came from the core Illumina business; GRAIL, Illumina's cancer liquid biopsy subsidiary, recorded revenues of $10 million. Product revenue for the quarter totaled $1.07 billion, up 12%, and Service and other revenue amounted to…

Benzinga

Jazz Pharma Reports Q1 Epidiolex Sales Increased 6% To $157.9M YoY

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) released financial results for the first quarter of 2022.

Benzinga

FDA Accepts AstraZeneca's sBLA for Imfinzi (durvalumab) in biliary tract cancer (BTC) with Priority Review

The U.S. Food and Drug Administration (FDA) has accepted AstraZeneca's (NASDAQ: AZN) supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab), in combination with standard-of-care chemotherapy and granted Priority Review for patients with locally advanced or metastatic biliary tract cancer (BTC).

Benzinga

Clovis Oncology: Q1 Earnings Insights

Clovis Oncology (NASDAQ:CLVS) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Benzinga

Earnings Scheduled For May 4, 2022

Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.

1 … 9 10 11 12

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Brain Tumour Research

Jazz Pharmaceuticals plc

44 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.